Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.60 |
| ▸ | EGFR | P00533 | 2/20 | 0.60 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.58 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.58 |
| ▸ | LCK | P06239 | 2/20 | 0.57 |
| ▸ | ITK | Q08881 | 1/20 | 0.57 |
| ▸ | KIT | P10721 | 1/20 | 0.55 |
| ▸ | FLT3 | P36888 | 1/20 | 0.55 |
| ▸ | LYN | P07948 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24196614 | 0.97 | BTK (0.57) | BTKEGFRNUDT14NUDT5LCK | |
| SCHEMBL30416245 | 0.97 | BTK (0.57) | BTKEGFRNUDT14NUDT5LCK | |
| SCHEMBL30331087 | 0.93 | BTK (0.58) | BTKEGFRNUDT14NUDT5LCK | |
| SCHEMBL30415972 | 0.93 | BTK (0.58) | BTKEGFRNUDT14NUDT5LCK | |
| SCHEMBL24192714 | 0.93 | BTK (0.58) | BTKEGFRNUDT14NUDT5LCK | |
| SCHEMBL24196616 | 0.93 | BTK (0.58) | BTKEGFRNUDT14NUDT5LCK | |
| SCHEMBL24196863 | 0.92 | BTK (0.57) | BTKEGFRNUDT14NUDT5LCK | |
| SCHEMBL24197325 | 0.91 | EGFR (0.63) | BTKEGFRNUDT14NUDT5LCK | |
| SCHEMBL15915403 | 0.91 | BTK (0.70) | BTKEGFRNUDT14NUDT5LCK | |
| SCHEMBL27949504 | 0.91 | BTK (0.70) | BTKEGFRNUDT14NUDT5LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248833-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
| US-20230248833-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
| US-20230248833-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
| EP-4180432-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2023-05-17 | — | — | EP | disclosed |
| CN-116134028-A | Compound capable of degrading BTK kinase, preparation method and pharmaceutical application thereof | 四川海思科制药有限公司 | 2023-05-16 | — | — | CN | disclosed |
| WO-2022007824-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | 四川海思科制药有限公司 | 2022-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248833-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | BTK, WEE1, WEE2 | BTK 1/4885EGFR 2234/4885NUDT14 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.